Capmatinib: Phase II data

Data from 65 evaluable adults with EGFR-mutated, c-MET-amplified NSCLC who progressed after single agent EGFR TKI therapy in the dose-expansion

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE